

**Help contribute to**  
**CAA**  
**RESEARCH**

**Introducing the cAPPricorn-1 clinical trial for people living with cerebral amyloid angiopathy (CAA)**

cAPPricorn-1 is researching an investigational medication called mivelsiran to see if it could be safe and effective.

Participating in this trial may be an opportunity to contribute to CAA research.

---

**WHO CAN JOIN?**

**Participants with sporadic CAA:**

- 50 years of age or older
- Have received a diagnosis of CAA from their doctor

**Participants with Dutch-type CAA:**

- 30 years of age or older
- Have a known gene mutation for Dutch-type CAA

Additional criteria will be assessed by the study team to determine your eligibility.

---

For more information reach out to the study team:

**Sanders Brown Center on  
Aging  
Contact: 859-323-1331**



**cAPPricorn-1**